


Form PTO-1449

US DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 1 of 1



Comple known

Application Number	10/541,108
Filing Date	June 30, 2005
First Named Inventor	Takuji KAKIGAMI
Art Unit	1614
Examiner Name	Not assigned
Confirmation No.	4940
Attorney Docket No.	868_008

**U.S. PATENT DOCUMENTS**

Exam. Initial		Document Number	Date	Name	Our Docket No.	Class	Sub Class	Filing Date
/SY/	AA	2002/0193390	12/19/2002	Villhauer				
/SY/	AB	6,011,155	01/04/2000	Villhauer				
/SY/	AC	2004/0180925	09/16/2004	Matsuno et al.				
/SY/	AD	5,939,560	08/17/1999	Jenkins et al.				
/SY/	AE	6,303,661	10/16/2001	Demuth et al.				

**FOREIGN PATENT DOCUMENTS**

		Document Number	Date	Country	Class	Sub Class	Translation	Abstract
/SY/	AF	02/051836	07/04/2002	WO				✓
/SY/	AG	1 354 882	10/22/2003	EP				
/SY/	AH	01/96295	12/20/2001	WO				
/SY/	AI	09-509921	10/07/1997	JP				✓
/SY/	AJ	97/40832	11/06/1997	WO				✓

**OTHER DOCUMENTS**

(Including Author, Title, Date, Pertinent Pages etc.)

/SY/	AK	Edwin B. Villhauer, Gary M. Coppola, and Thomas E. Hughes, Novartis Institute for Biomedical Research, Summit, NJ 07901, "Chapter 19. DPP-IV Inhibition and Therapeutic Potential," Section IV-Immunology, Endocrinology and Metabolic Diseases, Hagmann, Ed., Annual Reports in Medicinal Chemistry-36, pp. 191-200, Copyright©2001 by Academic Press

Examiner:	/Shawquia Young/	Date Considered:	03/28/2007
-----------	------------------	------------------	------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.